Optagon Labs is an AI-native R&D company that helps drug developers co-optimize multiple drug properties simultaneously using digital twins, reducing the time and cost of pre-clinical drug engineering. Its frontier model integrates a molecular foundation model, state representation architecture, and an optimizer that selects the most informative next experiment. The platform reasons across hit-to-lead, lead optimization, candidate selection, and early CMC stages to de-risk the path to clinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
Drug engineering—the process of optimizing a molecule for solubility, stability, safety, permeability, and manufacturability—remains a bottleneck in pharmaceutical development, often consuming 5+ years and tens of millions of dollars. Teams of up to 300 scientists run siloed, manual experiments across multiple stages (hit-to-lead, lead optimization, candidate selection, early CMC), and design decisions made early can lock in constraints that surface as toxicity, poor exposure, or formulation failures in clinical trials. Most biotechs lack the AI infrastructure to address this multi-variable, sequential search problem under high uncertainty.
Solution
Optagon Labs provides an AI-native R&D service that brings the entire drug development program into one digital twin, modeling the molecule, formulation, process, and the body simultaneously. The system co-optimizes multiple drug properties at once by running design–make–test loops across internal and external labs, selecting only the high-value experiments that resolve the most uncertainty. Its frontier model comprises three integrated components: a molecular foundation model, a state representation architecture, and an optimizer that decides which experiment to run next. Every decision is interpretable and carries its uncertainty and provenance, allowing drug developers to converge rapidly on optimal designs that satisfy potency, ADMET, and CMC targets before entering clinical trials.
Target Audience
Primary customers are biotech companies and pharmaceutical firms that need to engineer drug leads into clinical candidates faster and with lower risk, particularly small biotechs operating on finite runway that cannot build their own frontier AI capabilities.
Features
- Digital twin that simultaneously models the drug lead's molecule, formulation, process, and physiological environment across all four development stages
- Co-optimization of coupled parameters (e.g., core scaffold, logD, pKa, salt form, particle size, crystallisation solvent) against targets like potency, hERG margin, oral exposure, and impurity profile
- AI-driven experiment selection that runs only the tests that maximally reduce program-level uncertainty, avoiding wasteful trial-and-error
- Frontier model integrating a molecular foundation model, a state representation architecture, and a sequential optimizer—not siloed single-endpoint predictors
- Interpretable decisions with provenance tracking, enabling traceability from design choices to clinical outcomes
- Human-in-command orchestration with modular AI accelerators that share context across different R&D endpoints, versus fully autonomous black-box systems